Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mary C. Smolskis
Observed names:
M Smolskis,
M. C. Smolskis,
M. Smolskis,
Mary C Smolskis,
Mary Smolskis
Institutions:
National Institutes of Health,
National Institute of Allergy and Infectious Diseases
Observed institutions:
National Institutes of Health,
London School of Hygiene & Tropical Medicine,
National Institute of Allergy and Infectious Diseases
OpenAlex ID:
A5022899529
Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease
2000
·
Sean Emery
, William B. Capra
, et al.
·
The Journal of Infectious Diseases
·
103
Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers
1991
·
V. L. Kan
, J. E. Bennett
, et al.
·
The Journal of Infectious Diseases
·
93
Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness
2019
·
Ana E Gamiño-Arroyo
, M Lourdes Guerrero
, et al.
·
Clinical Infectious Diseases
·
63
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022
·
ACTIV-3/TICO Study Group
, Angela J. Rogers
, et al.
·
Annals of Internal Medicine
·
60
PDF
Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients
2017
·
John H. Powers
, Elizabeth D. Bacci
, et al.
·
Value in Health
·
46
PDF
A randomized trial comparing concise and standard consent forms in the START trial
2017
·
Christine Grady
, Giota Touloumi
, et al.
·
PLoS ONE
·
42
PDF
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
2022
·
ACTIV-3/TICO Study Group*
, Christina Barkauskas
, et al.
·
Annals of Internal Medicine
·
31
PDF
Immune‐Globulin Prophylaxis of Respiratory Syncytial Virus Infection in Patients Undergoing Stem‐Cell Transplantation
2002
·
K. Cortez
, B. R. Murphy
, et al.
·
The Journal of Infectious Diseases
·
31
PDF
Beating the odds: Successful establishment of a Phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak
2016
·
J. Doe-Anderson
, B. Baseler
, et al.
·
Contemporary Clinical Trials Communications
·
28
PDF
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
2024
·
Aurélie Wiedemann
, Edouard Lhomme
, et al.
·
Nature Communications
·
23
PDF
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults
2023
·
Andrew W Lee
, Ken Liu
, et al.
·
Clinical Infectious Diseases
·
19
PDF
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries
2021
·
Moses Badio
, Edouard Lhomme
, et al.
·
Trials
·
18
PDF
A unique immune signature of serum cytokine and chemokine dynamics in patients with Zika virus infection from a tropical region in Southern Mexico
2020
·
Joaquín Zuñiga
, José Alberto Choreño-Parra
, et al.
·
International Journal of Infectious Diseases
·
16
PDF
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024
·
Neil R Aggarwal
, Jacquie Nordwall
, et al.
·
Clinical Infectious Diseases
·
15
PDF
“Differential risk of hospitalization among single virus infections causing influenza‐like illnesses”
2018
·
Ana A. Ortiz‐Hernández
, Katherine K. Nishimura
, et al.
·
Influenza and Other Respiratory Viruses
·
12
PDF
Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)
2022
·
Irini Sereti
, Kathryn Shaw-Saliba
, et al.
·
PLoS ONE
·
10
PDF
SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali
2024
·
Sylvain Laverdure
, Donatien Kazadi
, et al.
·
International Journal of Infectious Diseases
·
8
NIAID ClinRegs—a Public Database of Country Clinical Research Regulatory and Ethics Requirements: Design and Utilization Analysis
2021
·
Jonathan Kagan
, Geoffrey N Goodman
, et al.
·
Clinical Infectious Diseases
·
5
Reported consent processes and demographics: a substudy of the INSIGHT S trategic T iming of AntiRetroviral T reatment ( START ) trial
2015
·
E Denning
, S Sharma
, et al.
·
HIV Medicine
·
5
Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial
2024
·
Simon Valayer
, Marie Alexandre
, et al.
·
Emerging Microbes & Infections
·
4
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
2023
·
Tomas O Jensen
, Greg A Grandits
, et al.
·
The Journal of Infectious Diseases
·
4
PDF
Community-based hospitals: New partners for government-sponsored clinical research during public health emergencies
2021
·
Laura A. McNay
, Gretchen Arnoczy
, et al.
·
Vaccine
·
3
Development and Implementation of Clinical Trial Protocol Templates at the National Institute of Allergy and Infectious Diseases
2009
·
Heather Bridge
, Mary Smolskis
, et al.
·
Clinical Trials
·
2
Measurement of binding antibodies to SARS-CoV-2 variants elicited by natural infection and COVID-19 vaccines in a sub-Saharan African population
2026
·
Eddy Kinganda Lusamaki
, Ana M. Ortega-Villa
, et al.
·
Scientific Reports
PDF
Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials
2026
·
Christian Møller Jensen
, Ramtin Zargari Marandi
, et al.
·
JAMIA Open
Show more works
View as search
Works count:
36
Citation count:
703
H-index:
15
I10-index:
17
Year
Topic
Type
